Mayfield Education and Research Foundation Funding Helps Researchers Unravel Important Role of Rb Tumor Suppressor in Aggressive Form of Breast Cancer

 

Dr. James Driscoll

James Driscoll, MD, PhD

CINCINNATI— The retinoblastoma (Rb) protein plays a critical role in suppressing the multi-step process of cell migration through the bloodstream, lymphovascular invasion and the metastasis of an aggressive type of breast cancer to the lung, researchers at the University of Cincinnati Cancer Institute and the UC Brain Tumor Center have found.

 

The findings of Rb’s role at multiple points in the disease process point to a potential new therapeutic target in patients with the most aggressive subset of breast cancer, known as basal-like breast carcinomas. This type of cancer has no estrogen receptor expression, and to date there is no efficient therapy for patients who suffer from it, leaving them with a generally poor prognosis. Basal-like breast carcinomas  spread to the lungs in about 25 percent of cases and to the brain in about 30 percent of cases.

 

The findings are published online today [Dec. 4] in the journal PLOS ONE. The investigator-initiated research was funded by the Department of Cancer Biology’s Startup Fund, the UC Dean’s Fund and the Mayfield Education and Research Foundation.   “Our research suggests that Rb inhibits collective cell migration, which in turn inhibits the lymphovascular invasion, the release of cancer cells into the blood circulation and the growth of metastasis,” says Samuel Godar, PhD, who led the study while Assistant Professor in the Department of Cancer Biology.  Dr. Godar is now Visiting Assistant Professor of Cancer Biology and President of BioTest4U, a biotech startup based in Loveland, Ohio, and in Covington, Ky.

 

The deadly progression begins when decreased levels of Rb are coupled with an increase in the expression of an oncoprotein (a gene that has the potential to cause cancer) called CD44. Basal-like breast carcinomas are known to have an elevated expression of CD44 and relatively low levels of Rb. Expression of the oncoprotein CD44 is required for the breast cancer cells to move actively through the bloodstream.

The researchers studied Rb in two different ways. They studied its ability to suppress collective cell migration in cultures at the Vontz Center for Molecular Studies. They also studied Rb in an animal model, examining its ability to suppress the release of single cancer cells and cancer cell clusters into the bloodstream.

 

“Our results suggest that Rb suppression stimulates an array of pathological consequences,” says co-investigator James Driscoll, MD, PhD, Assistant Professor in the Division of Hematology-Oncology. “It stimulates collective rather than single cell-based invasion and migration; it leads to lymphovascular invasion; and it orchestrates metastasis to remote organs through the bloodstream.”

 

Samuel Godar, PhD

Samuel Godar, PhD

The research illuminates the crucial role of the Rb/CD44 pathway in the metastatic progression of basal-like breast carcinomas, Dr. Godar says. 

“It points to the Rb/CD44 pathway as a promising target for therapy to combat the propensity for these aggressive breast cancers to metastasize to the lung and brain. About 90 percent of cancer patients die primarily because of metastatic disease. We believe that the complex analysis of metastatic progression in a preclinical model, such as the analysis we used, will become essential for predicting the true powers of novel anti-cancer drugs."

 

Additional co-investigators of the study were Kui-Jin Kim, Alzbeta Godarova and Kari Seedle of UC’s Department of Cancer Biology; Min-Ho Kim of Ulsan University Hospital in Ulsan, Republic of Korea; Tan A. Ince of the University of Miami Miller School of Medicine; and Susanne I. Wells of Cincinnati Children's Hospital Medical Center.

 

December 05, 2013

FOR IMMEDIATE RELEASE

CONTACT:
Cindy Starr, MSJ
Communications Department
513-558-3505

 
The findings of Rb’s role at multiple points in the disease process point to a potential new therapeutic target in patients with the most aggressive subset of breast cancer.
 

Mayfield Education & Research Foundation

3825 Edwards Road - Suite 300
Cincinnati, OH 45209
Phone: 513.569.5277 | Fax: 513.569.5365

moreinfo@mayfieldfoundation.org

Copyright 2018 - Mayfield Education & Research Foundation